Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$0.89 USD
-0.07 (-7.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.90 +0.01 (1.01%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.89 USD
-0.07 (-7.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.90 +0.01 (1.01%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth C Momentum C VGM
Zacks News
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
by Zacks Equity Research
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
by Zacks Equity Research
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
by Zacks Equity Research
Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.
Bio-Path (BPTH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Radius Completes Enrollment in Phase III Osteoporosis Study
by Zacks Equity Research
Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Onconova's Cancer Study Fails to Meet Endpoint, Shares Down
by Zacks Equity Research
Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.
Bio-Path (BPTH) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Denny's, Heico, Oasis Midstream Partners, NV5 Global and Bio-Path
by Zacks Equity Research
Zacks.com featured highlights include: Denny's, Heico, Oasis Midstream Partners, NV5 Global and Bio-Path
Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Path Leukemia Combo Study Shows Positive Early Data
by Zacks Equity Research
Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.
Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
by Zacks Equity Research
Bio-Path Holdings, Inc. (BPTH) shares rose over 13% in the last trading session.